RWE GENESYSNanoparticles are changing the face of biomedical research

Nanoparticles are changing the face of biomedical research

For effective treatment of a brain tumour anticancer drugs must gain access to tumour cells, however many tumours have a poorly formed blood vascular system with poor rates of blood flow. This blood–brain–tumour barrier can block drugs that could be very effective for treating tumours.

Nanoparticles provide a mode of cancer drug delivery by acting as carriers, facilitating the entry of the cancer drug through windows in tumour vasculature, allowing direct tumour cell access (Bannerjee, D., Harfouche, R. and Sengupta,S., 2011; Haley, B. and Frenkel, E., 2008).

Convection-enhanced delivery (CED) has also shown promise to bypass this barrier through the delivery of drugs through one to several catheters placed stereotactically (a method in neurosurgery and neurological research for locating points within the brain using an external, three-dimensional frame of reference) directly within the tumour mass or around the tumour (Debinsky, W., 2009).

The recent King et al. study with rats (2017)  found that combining CED with nanoparticles to get drugs past the blood-brain barrier allows sustained drug release and minimal toxicity thus increasing drug efficiency.  This supports nanotechnology as an exciting platform in the field of anticancer research which promises to improve the pharmacology of current cancer therapeutics.

References

Banerjee, D., Harfouche, R. and Sengupta, S. (2011), Nanotechnology-mediated targeting of tumor angiogenesis, Vascular Cell, 2011, 3:3, Available at https://www.ncbi.nlm.nih.gov/pubmed/21349160 [Accessed 03.08.17]

Debinski, W. and Tatter, S.B. (2009), Convection-enhanced delivery for the treatment of brain tumors, Expert Review of Neurotherapeutics, 2009 Oct;9(10):1519-27. Available at https://www.ncbi.nlm.nih.gov/pubmed/19831841 [Accessed 03.08.17]

Haley, B., Frenkel, E. (2008), Nanoparticles for drug delivery in cancer treatment, Urologic Oncology, 2008 Jan-Feb;26(1):57-64. Available at https://www.ncbi.nlm.nih.gov/pubmed/18190833 [Accessed 03.08.17]

King, A. et al. (2017), Local DNA repair inhibition for sustained radiosensitization in high grade gliomas, Molecular Cancer Therapy, May 31 2017 Available at http://mct.aacrjournals.org/content/early/2017/05/31/1535-7163.MCT-16-0788  [Accessed 03.08.17]

Meyers et al. (2013), Nanoparticles for imaging and treating brain cancer, Nanomedicine (Lond), 2013 Jan; 8(1): 123-143. Available at https://www.ncbi.nlm.nih.gov/pubmed/23256496 [Accessed 03.08.17]

.

REACH OUT TODAY

Arrange a call back...

Please leave this field empty.
curve
curve

Latest News

Colette Hamilton, CEO, speaker at sponsored event, Pharma Pricing & Market Access EU 2018. Talk title; Redefining HEOR practice to meet the needs of a 21st century healthcare system:the economist’s perspective.

Colette Hamilton, CEO, speaker at sponsored event, Pharma Pricing & Market Access EU 2018. Talk title; Redefining HEOR practice to meet the needs of a 21st century healthcare system:the economist’s perspective.

Read
CEO Colette Hamilton attends the UKs first LinkedInLocal networking event in the North, at the UKFast headquarters. Exciting collaborations in Manchester, the heart of the UKs Northern Tech Powerhouse

CEO Colette Hamilton attends the UKs first LinkedInLocal networking event in the North, at the UKFast headquarters. Exciting collaborations in Manchester, the heart of the UKs Northern Tech Powerhouse

Read
RWE Genesys sponsor conference session at 4th Annual Pharmacon Asia 2017,  19-22 September, One Farrer Hotel & Spa, Singapore

RWE Genesys sponsor conference session at 4th Annual Pharmacon Asia 2017, 19-22 September, One Farrer Hotel & Spa, Singapore

Read
Nanoparticles are changing the face of biomedical research

Nanoparticles are changing the face of biomedical research

Read